Mitek to Participate in Benchmark Discovery One-on-One Conference

SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Mitek (NASDAQ: MITK), a global leader in mobile capture and digital identity verification solutions, today announced it has been invited to participate at the Benchmark 8th Annual Discovery 1x1 Conference taking place Wednesday, December 4, 2019 at The New York Athletic Club in New York City.

Mitek’s CFO Jeff Davison will host one-on-one and small group meetings with institutional investors throughout the day.

For additional information or to schedule a one-on-one meeting with Mitek, please contact your Benchmark representative, or MKR Investor Relations, Mitek’s investor relations firm, at [email protected].

About MitekMitek (NASDAQ: MITK) is a global leader in mobile capture and digital identity verification solutions built on the latest advancements in computer vision and machine learning. Mitek’s identity verification solutions enable an enterprise to verify a user’s identity during a digital transaction, which assists businesses operating in highly regulated markets to reduce financial risk and meet regulatory requirements while increasing revenue from digital channels. Financial services, marketplaces and other organizations around the world use Mitek to reduce friction creating the digital experiences their customers expect. Mobile Deposit® and Mobile Verify® are used by millions of consumers for check deposit, new account opening and more. The company is based in San Diego with offices in New York, London, Amsterdam, Barcelona, Paris and St Petersburg. Learn more at www.miteksystems.com. [(MITK-F)]

Follow Mitek on LinkedIn: http://www.linkedin.com/company/mitek-systems-inc Follow Mitek on Twitter: @miteksystems Connect with Mitek on Facebook: http://www.facebook.com/MitekSystems See Mitek on YouTube: http://www.youtube.com/miteksystems Read Mitek’s latest blog post: http://www.miteksystems.com/blog

Investor Contact: Todd Kehrli or Jim Byers MKR Investor Relations, Inc. [email protected]

You May Also Be Interested In

• Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
• Form 8.3 - LondonMetric Property Plc & Schroder REIT Ltd
• Form 8.3 - Cordel Group Plc